SMARCB1 and colorectal cancer: To determine the effects of SP-2577 on SWI/SNF-mutant cell viability, we performed drug-dose-response (DDR) studies with 72 h CellTiterGlo viability endpoints in SCCOHT (SMARCA4-/-), OCCC (ARID1A-/-), lung (SMARCA4-/-), kidney (SMARCB1-/-), and colorectal cancer cell lines (SMARCA4-/-).